secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001193125-23-076682
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Pharma reports FY2022 JELMYTO revenue of $64.4M (+34% YoY); guides FY2023 revenue $76-86M
--------------------------------------------------------------------------------

- JELMYTO net revenue for FY2022: $64.4M, up 34% from $48.0M in FY2021; Q4 revenue: $18.1M.
- Net loss for FY2022: $109.2M ($4.79/share) vs $110.8M ($4.96/share) in FY2021; cash ~$100M.
- UGN-102 Phase 3 ENVISION fully enrolled (~220 patients); topline data for ENVISION and ATLAS expected mid-2023; NDA submission targeted for 2024.
- FY2023 guidance: JELMYTO revenue $76-86M; operating expenses $135-145M; cash expected to fund operations into H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312523076682/0001193125-23-076682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312523076682/d680885d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-076682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer